Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Kennametal (NYSE: KMT) reported third quarter EPS of $0.47, $0.22 better than the analyst estimate of $0.25. Revenue for the quarter came in at $486.39M versus the consensus estimate of $488.54M.
Guidance
Kennametal sees FY 2025 EPS of $1.30-$1.45 versus the analyst consensus of $1.13.
Kennametal sees FY 2025 revenue of $1.97B-$1.99B versus the analyst consensus of $1.97B.
Kennametal’s stock price closed at $19.82. It is down -11.04% in the last 3 months and down -21.81% in the last 12 months.
Kennametal saw 0 positive EPS revisions and 9 negative EPS revisions in the last 90 days. See Kennametal’s stock price’s past reactions to earnings here.
According to InvestingPro, Kennametal’s Financial Health score is "fair performance".
Check out Kennametal’s recent earnings performance, and Kennametal’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar